Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis

Abstract Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Even with a high disease control rate, a majority of patients develop acquired EGFR-TKIs r...

Full description

Bibliographic Details
Main Authors: Di Hu, Yan-Yan Zhou, Hong-Bo Ma, Miao-Miao Tao, Qun-Zhen Huang, Zhen-Zhou Yang, Qi Zhou
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Pulmonary Medicine
Subjects:
NSCLC
EGFR mutation
EGFR-TKIs
Angiogenesis inhibitors
Meta-analysis
Online Access:https://doi.org/10.1186/s12890-023-02472-x

Internet

https://doi.org/10.1186/s12890-023-02472-x

Similar Items